SAN DIEGO, April 02, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has accepted an invitation
to participate in the H.C. Wainwright Global Life Sciences Conference (April 7-9 in London). Conatus senior management will conduct
a series of scheduled meetings with investment professionals and present a company overview on Tuesday, April 9, 2019, from 10:30
a.m. to 10:50 a.m. BST (5:30 a.m. to 5:50 a.m. EDT). A webcast of the presentation will be available live and archived in the
Investors section of the Conatus website at www.conatuspharma.com.
About Conatus Pharmaceuticals
Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases
with significant unmet need. In collaboration with Novartis, Conatus is developing its lead in-licensed compound, emricasan, for
the treatment of patients with NASH-driven chronic liver diseases. Conatus is independently developing its lead internally
developed compound, CTS-2090, for the treatment of patients with chronic diseases involving inflammasome pathways. For additional
information, please visit www.conatuspharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical facts contained in this press release are forward looking
statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,”
“plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or
“continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the
date of this press release and are subject to a number of risks, uncertainties and assumptions, including those risks described in
the company’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. The
events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results
could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company
does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new
information, future events, changed circumstances or otherwise.
CONTACT: Alan Engbring
Conatus Pharmaceuticals Inc.
(858) 376-2637
aengbring@conatuspharma.com